Anticancer agents from natural products (Record no. 11579)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 05438nam a2200373Ia 4500 |
| 001 - CONTROL NUMBER | |
| control field | CRC0KE10649PDF |
| 003 - CONTROL NUMBER IDENTIFIER | |
| control field | BD-DhSAU |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20151012144304.0 |
| 006 - FIXED-LENGTH DATA ELEMENTS--ADDITIONAL MATERIAL CHARACTERISTICS | |
| fixed length control field | m|||||o||d|||||||| |
| 007 - PHYSICAL DESCRIPTION FIXED FIELD--GENERAL INFORMATION | |
| fixed length control field | cr|||| |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 111202s2012 fluadf s 000 0 eng d |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| International Standard Book Number | 9781439813836 (ebook : PDF) |
| 040 ## - CATALOGING SOURCE | |
| Original cataloging agency | BD-DhSAU |
| Transcribing agency | BD-DhSAU |
| 090 ## - LOCALLY ASSIGNED LC-TYPE CALL NUMBER (OCLC); LOCAL CALL NUMBER (OCLC) | |
| Classification number (OCLC) (R) ; Classification number, CALL (RLIN) (NR) | RS431.A64 |
| Local cutter number (OCLC) ; Book number/undivided call number, CALL (RLIN) | A562 2012 |
| 092 ## - LOCALLY ASSIGNED DEWEY CALL NUMBER (OCLC) | |
| Classification number | 616.994061 |
| Item number | A629 |
| 245 00 - TITLE STATEMENT | |
| Title | Anticancer agents from natural products |
| Medium | [electronic resource] / |
| Statement of responsibility, etc. | edited by Gordon M. Cragg, David G.I. Kingston, David J. Newman. |
| 250 ## - EDITION STATEMENT | |
| Edition statement | 2nd ed. |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. (IMPRINT) | |
| Place of publication, distribution, etc. | Boca Raton : |
| Name of publisher, distributor, etc. | CRC Press, |
| Date of publication, distribution, etc. | 2012. |
| 300 ## - PHYSICAL DESCRIPTION | |
| Extent | xv, 751 p., [16] p. of plates : |
| Other physical details | ill. (some col.). |
| 505 0# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | ch. 1. Introduction / Gordon M. Cragg, David G.I. Kingston, and David J. Newman -- ch. 2. Camptothecin and its analogs / Nicolas J. Rahier, Craig J. Thomas, and Sidney M. Hecht -- ch. 3. The discovery and development of the combretastatins / Kevin G. Pinney ... [et al.] -- ch. 4. Homoharringtonine and related compounds / Hideji Itokawa, Yukio Hitotsuyanagi, and Kuo-Hsiung Lee -- ch. 5. Podophyllotoxins and analogs / Kuo-Hsiung Lee and Zhiyan Xiao -- ch. 6. Taxol and its analogs / David G.I. Kingston -- ch. 7. The vinca alkaloids / Fanny Roussi, Fran�coise Gu�eritte, and Jacques Fahy -- ch. 8. The bryostatins / David J. Newman -- ch. 9. The isolation, characterization, and development of a novel class of potent antimitotic macrocyclic depsipeptides : the cryptophycins / Rima S. Al-awar and Chuan Shih -- ch. 10. Chemistry and biology of the discodermolides, potent mitotic spindle poisons / Sarath P. Gunasekera and Amy E. Wright -- ch. 11. The dolastatins : novel antitumor agents from Dolabella auricularia / Erik Flahive and Jayaram Srirangam -- ch. 12. Ecteinascidin-743 (Yondelis), Aplidin, and Irvalec / Carmen Cuevas ... [et al.] -- ch. 13. Discovery of E7389, a fully synthetic macrocyclic ketone analog of halichondrin B / Melvin J. Yu, Yoshito Kishi, and Bruce A. Littlefield -- |
| 505 8# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | ch. 14. HTI-286 (Taltobulin), a synthetic analog of the antimitotic natural product hemiasterlin / Raymond J. Andersen ... [et al.] -- ch. 15. The actinomycins / Anthony B. Mauger and Helmut Lackner -- ch. 16. Anthracyclines / Federico-Maria Arcamone -- ch. 17. Ansamitocins (Maytansinoids) / Tin-Wein Yu ... [et al.] -- ch. 18. Benzoquinone ansamycins / Kenneth M. Snader -- ch. 19. Bleomycin group antitumor agents / Sidney M. Hecht -- ch. 20. Biochemical and biological evaluation of (+)-CC-1065 analogs and conjugates with polyamides / Rohtash Kumar and J. William Lown -- ch. 21. Epothilone, a myxobacterial metabolite with promising antitumor activity / Gerhard H�ofle and Hans Reichenbach -- ch. 22. Enediynes / Philip R. Hamann, Janis Upeslacis, and Donald B. Borders -- ch. 23. The mitomycins / William A. Remers -- ch. 24. Staurosporines and structurally related indolocarbazoles as antitumor agents / Michelle Prudhomme -- ch. 25. Combinatorial biosynthesis of anticancer natural products / Steven G. Van Lanen and Ben Shen -- ch. 26. Developments and future trends in anticancer natural products drug discovery / Gordon M. Cragg and David J. Newman. |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | "The search for new lead compounds is a crucial element of modern pharmaceutical research. Natural products provided the only source of pharmaceuticals for thousands of years, and natural products have made enormous contributions to human health through compounds such as quinine, morphine, aspirin (a natural product analog), digitoxin, and many others. The potential of natural products as anticancer agents was recognized in the 1950's by the U. S. National Cancer Institute (NCI) under the leadership of the late Dr. Jonathan Hartwell, and the NCI has since made major contributions to the discovery of new naturally occurring anticancer agents through its contract and grant support, including an important program of plant and marine collections. Many, although not all, of the compound classes described in the following pages owe their origin in whole or in part to NCI support. In spite of the success of the natural products approach to anticancer drug discovery, as exemplified by the following chapters, in recent years their importance as a source of molecular diversity for drug discovery research and development has been overshadowed by newer chemical approaches currently in favor. These approaches include chemical ones which make heavy use of combinatorial chemistry, and biological ones such as manipulation of biosynthetic pathways of microbial metabolites through combinatorial biosynthetic techniques. It is thus worthwhile to review briefly the major reasons why natural products are so important. First, there is a strong biological and ecological rationale for plants and marine invertebrates to produce novel bioactive secondary metabolites"-- |
| Assigning source | Provided by publisher. |
| 530 ## - ADDITIONAL PHYSICAL FORM AVAILABLE NOTE | |
| Additional physical form available note | Also available in print edition. |
| 538 ## - SYSTEM DETAILS NOTE | |
| System details note | Mode of access: World Wide Web. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name as entry element | Antineoplastic agents. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name as entry element | Pharmacognosy. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name as entry element | Natural products. |
| 655 #7 - INDEX TERM--GENRE/FORM | |
| Genre/form data or focus term | Electronic books. |
| Source of term | lcsh |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Cragg, Gordon M. L. |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Kingston, David G. I. |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Newman, David J. |
| 776 1# - ADDITIONAL PHYSICAL FORM ENTRY | |
| International Standard Book Number | 9781439813829 (hardback) |
| 856 40 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="http://marc.crcnetbase.com/isbn/9781439813836">http://marc.crcnetbase.com/isbn/9781439813836</a> |
| Electronic format type | application/PDF |
No items available.